Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05052671 · ClinicalTrials.gov registry record
ctDNA Assay in Patients With Resectable Pancreatic Cancer
A clinical trial of Pancreas Cancer, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT05052671: Recruiting study of Pancreas Cancer, sponsored by University of Oklahoma.
NCT05052671 is a study of Pancreas Cancer that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 50 participants, below the 906-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05052671, a study of Pancreas Cancer, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may provide preliminary evidence that helps improve future patient care through targeted diagnostics, prognosis, and/or treatment.
Primary Outcome
Determine the proportion of ct DNA positivity in patients with resectable pancreatic cancer.
Conditions Studied
Study Locations (2)
Oklahoma
- University of Oklahoma - Oklahoma City
- Stephenson Cancer Center- Tulsa - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2028-12 |
What NCT05052671 shows while recruiting
NCT05052671 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 906-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05052671 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05052671 about?
NCT05052671 is a clinical study titled "ctDNA Assay in Patients With Resectable Pancreatic Cancer". The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may pr...
What is the current status of trial NCT05052671?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-05-25. Estimated completion is 2028-12.
What conditions does trial NCT05052671 study?
This clinical trial studies the following conditions: Pancreas Cancer.
Who is sponsoring clinical trial NCT05052671?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05052671 being conducted?
This trial has 2 study locations across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05052671's enrollment target sits among peer trials
50 30th of 54 higher than 24 of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
RECRUITING · Phase 3
-
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI